SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sarah L. Greig, Carbidopa/levodopa enteral suspension in advanced Parkinson’s disease: a guide to its use, Drugs & Therapy Perspectives, 2016, 32, 5, 177

    CrossRef

  2. 2
    Diego Santos García, Juan Carlos Martínez Castrillo, Víctor Puente Périz, Agustín Seoane Urgorri, Servando Fernández Díez, Vicente Benita León, Beatriz Udaeta Baldivieso, Antonia Campolongo Perillo, Natividad Mariscal Pérez, Clinical management of patients with advanced Parkinson’s disease treated with continuous intestinal infusion of levodopa/carbidopa, Neurodegenerative Disease Management, 2016,

    CrossRef

  3. 3
    Anthony E. Lang, Ramon L. Rodriguez, James T. Boyd, Sylvain Chouinard, Cindy Zadikoff, Alberto J. Espay, John T. Slevin, Hubert H. Fernandez, Mark F. Lew, David A. Stein, Per Odin, Victor S.C. Fung, Fabian Klostermann, Alfonso Fasano, Peter V. Draganov, Nathan Schmulewitz, Weining Z. Robieson, Susan Eaton, Krai Chatamra, Janet A. Benesh, Jordan Dubow, Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials, Movement Disorders, 2016, 31, 4
  4. 4
    Michael Epstein, David A Johnson, Robert Hawes, Nathan Schmulewitz, Arvydas D Vanagunas, E Roderich Gossen, Weining Z Robieson, Susan Eaton, Jordan Dubow, Krai Chatamra, Janet Benesh, Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson’s Disease, Clinical and Translational Gastroenterology, 2016, 7, 3, e159

    CrossRef

  5. 5
    Jonathan Timpka, Tove Henriksen, Per Odin, Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?, Movement Disorders Clinical Practice, 2016, 3, 2
  6. 6
    A. Merola, A. Romagnolo, M. Zibetti, A. Bernardini, D. Cocito, L. Lopiano, Peripheral neuropathy associated with levodopa–carbidopa intestinal infusion: a long-term prospective assessment, European Journal of Neurology, 2016, 23, 3
  7. 7
    O. Băjenaru, A. Ene, B. O. Popescu, J. A. Szász, M. Sabău, D. F. Mureşan, L. Perju-Dumbrava, C. D. Popescu, A. Constantinescu, I. Buraga, M. Simu, The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience, Journal of Neural Transmission, 2016, 123, 4, 407

    CrossRef

  8. 8
    Lauren C Seeberger, Robert A Hauser, Carbidopa levodopa enteral suspension, Expert Opinion on Pharmacotherapy, 2015, 16, 18, 2807

    CrossRef

  9. 9
    Mark F. Lew, John T. Slevin, Rejko Krüger, Juan Carlos Martínez Castrillo, Krai Chatamra, Jordan S. Dubow, Weining Z. Robieson, Janet A. Benesh, Victor S.C. Fung, Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials, Parkinsonism & Related Disorders, 2015, 21, 7, 742

    CrossRef

  10. 10
    Hubert H. Fernandez, David G. Standaert, Robert A. Hauser, Anthony E. Lang, Victor S.C. Fung, Fabian Klostermann, Mark F. Lew, Per Odin, Malcolm Steiger, Eduard Z. Yakupov, Sylvain Chouinard, Oksana Suchowersky, Jordan Dubow, Coleen M. Hall, Krai Chatamra, Weining Z. Robieson, Janet A. Benesh, Alberto J. Espay, Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results, Movement Disorders, 2015, 30, 4
  11. 11
    Oluwadamilola O Ojo, Hubert H Fernandez, Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease, Future Neurology, 2015, 10, 3, 191

    CrossRef

  12. 12
    Roongroj Bhidayasiri, Onanong Jitkritsadakul, Nonglak Boonrod, Rungsun Rerknimitr, Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy, Clinical Neurology and Neurosurgery, 2014, 116, 1

    CrossRef

  13. 13
    M. Zibetti, A. Merola, C. A. Artusi, L. Rizzi, S. Angrisano, D. Reggio, C. Angelis, M. Rizzone, L. Lopiano, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, European Journal of Neurology, 2014, 21, 2
  14. 14
    Christofer Lundqvist, Antonie Giæver Beiske, Ola Reiertsen, Ivar Sønbø Kristiansen, Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients, Journal of Neurology, 2014, 261, 12, 2438

    CrossRef

  15. 15
    H. Baas, J. Claßen, M. Gerlach, M. Schwarz, P. Themann, D. Woitalla, W. Jost, Should the maximum daily doses of levodopa be limited to 400mg/die?, Basal Ganglia, 2014, 4, 1, 29

    CrossRef

  16. 16
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  17. 17
    Wolfgang H Jost, Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration, Expert Opinion on Drug Safety, 2014, 13, 4, 447

    CrossRef

  18. 18
    Maria Papathanou, Rika Laan, Peter Jenner, Sarah Rose, Andrew C. McCreary, Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats, Movement Disorders, 2013, 28, 8
  19. 19
    Fabienne Sprenger, Werner Poewe, Management of Motor and Non-Motor Symptoms in Parkinson’s Disease, CNS Drugs, 2013, 27, 4, 259

    CrossRef

  20. 20
    A. H. V. Schapira, Progress in European neurology 2012–2013, European Journal of Neurology, 2013, 20, 12
  21. 21
    Onanong Jitkritsadakul, Priya Jagota, Sitthi Petchrutchatachart, Lalana Sansopha, Rungsun Rerknimitr, Roongroj Bhidayasiri, Recurrent pancreatitis as a rare complication of duodenal levodopa infusion treatment, Movement Disorders, 2013, 28, 9
  22. 22
    Karen L. Eskow Jaunarajs, David G. Standaert, Tacey X. Viegas, Michael D. Bentley, Zhihao Fang, Bekir Dizman, Kunsang Yoon, Rebecca Weimer, Paula Ravenscroft, Tom H. Johnston, Michael P. Hill, Jonathan M. Brotchie, Randall W. Moreadith, Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit, Movement Disorders, 2013, 28, 12
  23. 23
    Anders Johansson, Dag Nyholm, Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa–carbidopa intestinal gel in the absence of head-to-head comparisons, Basal Ganglia, 2012, 2, 4, 221

    CrossRef

  24. 24
    Dag Nyholm, Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety, Parkinsonism & Related Disorders, 2012, 18, 8, 916

    CrossRef

  25. 25
    A. H. V. Schapira, E. K. Tan, Optimizing treatment for Parkinson's disease, European Journal of Neurology, 2012, 19, 12